Table 1 Main minimum global policy options considered for the economic analysis. We assume that countries using IPV-only at T0 will continue to do so indefinitely regardless of the policy choice.
From: An economic analysis of poliovirus risk management policy options for 2013–2052
Policy abbreviation | Description | Characterization in countries using OPV-only at T0 (LOW, LMI, or UMI) | Characterization in countries using IPV/OPV at T0 (UMI or HIGH) |
|---|---|---|---|
RC with SIAs | Continued status quo | Continue tOPV-only indefinitely for RI supplemented with bOPV and tOPV SIAs | Continue IPV/OPV indefinitely supplemented with bOPV and tOPV SIAs |
RC no SIAs | Continued status quo, but with no SIAs from 1/1/2019 | Continue tOPV-only indefinitely for RI supplemented with bOPV and tOPV SIAs until 1/1/2019 | Continue IPV/OPV indefinitely supplemented with bOPV and tOPV SIAs until 1/1/2019 |
IPV5 | Current plan [19] with IPV everywhere for 5 years after all-OPV cessation | • Add IPV doses to RI schedule on 1/1/2015a | • Replace all tOPV with bOPV on 4/1/2016 |
• Replace all tOPV with bOPV on 4/1/2016 | • OPV13 cessation on 4/1/2019, switch RI to IPV-only indefinitely | ||
• OPV13 cessation on 4/1/2019b | |||
• IPV cessation on 4/1/2024 in LOW and LMI countries | |||
IPV10 | Current plan [19] with IPV everywhere for 10 years after all-OPV cessation | • Same as above but with IPV cessation of 4/1/2029 in LOW and LMI countries | • Same as above |
IPV through Tend | Current plan [19] with IPV everywhere until at least T end | • Same as above but without IPV cessation anywhere | • Same as above |
No IPV | Current plan [19] but without global IPV use after OPV cessation of any type | • Replace all tOPV with bOPV on 4/1/2016 | • Replace all tOPV with bOPV on 4/1/2016 |
• OPV13 cessation on 4/1/2019 | • OPV13 cessation on 4/1/2019, switch RI to IPV-only indefinitely |